Biotechnology News Magazine

Biotechnology News Magazine is one of the industry’s leading sources for biotech industry news!

Biotechnology News Magazine reports the latest biotech, pharma, FDA updates, biotechnology clinical trials, biotechnology mergers, biotechnology acquisitions, biotechnology funding, articles of interest and other important news.

Biotech executives, investors, and other allied health professionals have access to Biotechnology News Magazine through a complimentary subscription. Furthermore, as patients become more pro-active in researching various medical diseases and conditions, we are proud to boast they are subscribers of our publication as well.

We hope you find value in Biotechnology News Magazine’s overall purpose and objectives. BiotechnologyNews Magazine is the authoritative voice of biotechnology, bridging the industry to healthcare professionals, academia, government, venture capitalists, and the general public.

If you have any questions or comments, please feel free to contact us. Biotechnology News Magazine is a fast, 1,2,3, easy read! LEARN MORE.

Latest Biotech Industry News

Airway Therapeutics Completes Dose Escalation in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bronchopulmonary Dysplasia

April 11, 2023

Airway Therapeutics began recruiting patients on March 28, 2023, for daily treatment up to 7 days at the highest dose of zelpultide alfa (rhSP-D) following a Data Safety Monitoring Committee (DSMC) report of no safety concerns.

Roche introduces navify® Algorithm Suite, a digital library of medical algorithms that enhances clinical decision-making to optimise patient care

April 11, 2023

At the global HIMSS1 Conference, Roche showcases navify Algorithm Suite, a single platform offering clinicians access to medical algorithms generating insights to help improve care decisions.

Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.

April 11, 2023

Under the terms of Pharming's 2019 exclusive license agreement with Novartis for leniolisib, the corresponding first commercial sale of Joenja® triggers a $10 million milestone payment by Pharming to Novartis.

Mergers/Acquisitions/Funding

Russell Finex Helps Leading Pharmaceutical Company Meet High Levels Of Demand With The Russell Compact Sieve

February 21, 2023

To ensure the highest quality final product, the company reached out to Russell Finex for a high-capacity vibrating screen. After assessing the company’s requirements, Russell Finex recommended the Russell Compact Sieve® as the ideal solution for check-screening pharmaceutical powders due to its stainless-steel contact parts, and easy-to-clean strip down design.

EuMentis Therapeutics Inc. Announces the First Closing of a Targeted $40M Series B Financing to Advance Novel Therapeutics to Treat Autism Spectrum Disorder, Tourette Syndrome and Traumatic Brain Injury

February 15, 2023

EuMentis plans to initiate Phase 2 clinical trials with EM-113 in autism spectrum disorder (ASD) and EM-221 in Tourette syndrome (TS) in 2nd half of this year

Clinical Trials, Studies, Data

PathO3Gen Solutions UVZone® Proven 99.9993% Effective Against Candida Auris: Shoes and Floors in Healthcare Facilities Should Be Addressed as Outbreak Continues

April 11, 2023

PathO3Gen Solutions’ multi-patented UVZone Shoe Sanitizing Stations, when placed in high-traffic and high-risk areas, enhance healthcare facility infection control measures, and may improve overall hospital biosafety.

Genexine’s Long-acting Anemia Treatment GX-E4 Phase 3 Clinical Trial Interim Result Is Presented at WCN2023, Confirmed Non-inferiority Compared to Mircera

April 11, 2023

“We are highly excited about the result KG Bio is sharing. This clinical trial is an opportunity to once again prove the global competitiveness of GX-E4, developed through Genexine's proprietary hyFc platform technology.” Genexine’s CEO Neil Warma said, “We will continue to challenge the global market by further expanding labels for dialysis patients as well as the non-dialysis market together with our partner KG Bio.”

Views from Our Experts

How Biotech Businesses Can Benefit from Freelance Experts

February 21, 2023

Ashmita Das, CEO of open talent platform Kolabtree, shares some of Kolabtree freelancer’s success stories.

FDA Updates

Unravel Biosciences Reports Positive Feedback from FDA Pre-Ind Meeting on RVL001 RETT Syndrome Program

February 15, 2023

Richard Novak, Ph.D., Unravel Bioscience Co-Founder and CEO. "The successful completion of this key development milestone provides a great validation of Unravel's ability to rapidly move promising therapies into the clinic, much faster than most conventional approaches to drug development."

ADMA BioCenters Receives FDA Approval for its Eighth Plasma Collection Center, Located in Hammond, LA

February 8, 2023

In addition, ADMA BioCenters remains on-track to have all 10 plasma collection centers FDA-licensed by year-end 2023.

Executives on the Move

ImmPACT Bio Appoints Biren Amin, M.B.A. to its Board of Directors

February 8, 2023

Biren Amin has been the chief financial officer (CFO) and chief strategy officer of Pyramid Biosciences, Inc. since August 2022. He also serves as a co-director on the board of trustees of Axiom REACH Foundation, a non-profit organization focused on addressing public health disparities.

BerGenBio Announces the Establishment of Oncology Scientific Advisory Board

February 2, 2023

"We are very proud and honored to have assembled a group of leading international NSCLC experts to guide us as we investigate bemcentinib in 1st line NSCLC STK11m in combination with today's standard of care," said Cristina Oliva, M.D., Chief Medical Officer of BerGenBio. "Their expertise will play an integral role in our evaluation of bemcentinib and its potential to provide significant benefits to patients who today face a particularly poor prognosis."